Skip Navigation



Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Gastroenterology | Family Medicine
Disease Category: Constipation
Location: United States, FL

Clinical Trial Details


Research Study Summary

Do You Suffer from Constipation?


This is a Phase 3, open-label study to evaluate the efficacy and long-term safety of the study drug MOA-728 given subcutaneously in patients with opioid induced constipation. The study will last approximately 52 weeks with 15 office visits. You may be compensated for your time and travel upon completion of study.

Patient Inclusion Criteria:

  • Male/female age 18 or older
  • History of pain of a least 2 months before screening visit
  • Stable medication for at least 1 month before screening visit
  • Taking oral, trans dermal, intravenous, or subcutaneous opioids daily for at least 1 month, continued use for duration of study
  • History of constipation due to opioid use for 1 month before screening
  • Hard or lumpy stools for at least 25% of bowel movements, sesation or incomplete evacuation at least 25% of the time, use of manual maneuvers 25% of the time, fewer than 3 bowel movements per week
  • At least 1 bowel movement in the week prior to screening visit
  • Must use 2 forms of birth control throughout study

Patient Exclusion Criteria:

  • Diagnosis of bowel obstruction, fecal incontinence, rectal prolapse, or other GI disorder, history of inflammatory bowel disorder, IBS, or megacolon within 6 month
  • History of rectal bleeding unexplained by hemorrhoids or fissures
  • History of cancer within 5 years except BSS or BCC
  • History of chronic constipation before study
  • Drug or alcohol abuse within 1 year of first screening
  • Unstable hepatic, renal, pulmonary, cardiovascular (uncontrolled HTN), neurological, psychiatric, or any other unstable medical condition
  • Positive drug screen for substance not prescribed by physician
  • Received investigational drug within 4 weeks of study
  • Planned surgery during study
  • Allergy or sensitivity to opioids, derivitives or antagonists

To Learn more



Both Male and Female


18 and up

Overall Status



52 Weeks

Facility Type



Renstar Medical Research
104 SE 1st Ave., Suite B
Ocala, FL 34471
Phone: 352-629-5800

View Map

Research Center Information: Renstar Medical Research

CW ID: 154268

Date Last Changed: July 24, 2013

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.